Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
The merger combines CVS' pharmacies with Aetna's insurance business, blurring traditionally distinct lines in hopes of lowering costs. CVS also has one of largest pharmacy benefits managers through CVS Caremark and a major Medicare Part D plan sponsor through its SilverScript unit.
The final deal valued Aetna at $212 per share, CVS said in a press release, or about $70 billion, up from the previously agreed upon $207 per share, or roughly $69 billion. CVS will now need to integrate Aetna and start trying to accomplish its three main priorities: making health care local and accessible, simplifying how consumers access care and lowering costs.
"There's a lot of excitement and energy in both organizations, and folks are ready to roll up their sleeves and get to work," CVS CEO Larry Merlo told CNBC in an interview Wednesday.
Consumers won't immediately see any differences in their local stores, Merlo said. Early next year, CVS plans to start testing stores with added health services. These new locations will likely focus on managing common chronic conditions, adding more primary health services at CVS' MinuteClinics, guiding discharged hospital patients through their at-home plans and managing complex conditions.
From there, CVS will evaluate and tweak new store formats as necessary before rolling them out broadly.
"We'll be working hard so those opportunities will be coming as soon as possible," he said.
The two companies announced the deal in December 2017 and received preliminary approval from the Department of Justice in October. CVS needed final approval from state insurance regulators where Aetna sells its coverage. A handful of states opposed the combination, saying it would reduce competition and could leave consumers worse off.
In the end, CVS was able to persuade the state regulators to sign off on the acquisition. To win approval from California, CVS agreed to a number of conditions, including not raising premiums as a result of acquisition costs and keeping premium increases to a minimum. This came after Aetna said it would sell its Medicare Part D drug plan business to WellCare Health Plans for an undisclosed amount in order ease concerns about the overlap between the CVS and Aetna Medicare Part D plans.
On its third-quarter earnings call Nov. 6, CVS said it expects to save more than $750 million within two years of the deal closing. Merlo has promised the combined company will create a new data-driven health-care model that's more personal, convenient and tailored to individual patients than ever before.